Menu

Molecular pathology – the key to delivering personalised medicine

In this chapter, Dr. Matthew Clarke makes the case for improving the provision of molecular pathology testing and how pathologists and hospital administrators might collaborate to achieve this goal. Dr. Clarke explains that without molecular pathology, we are not able to understand cancer sub-types and optimize treatment choices for each patient. Molecular pathology is thus essential to improving patient outcomes. To unlock better cancer care, Dr. Clarke calls for greater emphasis on molecular pathology in pathology education, enhanced systems and networks to ensure efficiency and effectiveness, and improved communication and collaboration between pathologists and hospital administrators.

将 Knowledge Pathway 更新直接发送到您的收件箱。

Molecular pathology – the key to delivering personalised medicine

“Traditional histopathology still provides essential information for cancer diagnosis on cancer type and grade. However, we need to take better advantage of the opportunities that molecular pathology brings by providing a greater level of detail about each patient’s tumour. Molecular pathology is essential to the provision of personalised medicine, now and more so in the future. If we fail to utilise this opportunity to provide accurate, in-depth diagnosis at the very beginning of each patient’s treatment journey, the treatment outcomes for our patients may be significantly impaired, and the reputations of our hospitals and pathology service may suffer. Hospital administrators and pathologists are central to the delivery of an effective and efficient molecular pathology service that is able to grow to accommodate the continuous growth in molecular testing and personalised treatment options. By working together with other stakeholders and creating systems and networks, we can deliver, in a timely manner, personalised medicine based on best outcomes evidence that proves the worth of our healthcare services and improves the lives of all patients with cancer.”

Molecular pathology – the key to delivering personalised medicine

Leica Biosystems Knowledge Pathway content is subject to the Leica Biosystems website terms of use, available at: Legal Notice. The content, including webinars, training presentations and related materials is intended to provide general information regarding particular subjects of interest to health care professionals and is not intended to be, and should not be construed as, medical, regulatory or legal advice. The views and opinions expressed in any third-party content reflect the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents. Any links contained in the content which provides access to third party resources or content is provided for convenience only.

For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted. Leica Biosystems and the editors hereby disclaim any liability arising directly or indirectly from the use of the content, including from any drugs, devices, techniques or procedures described in the content.

Copyright © 2021 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.

想让我们展示你的作品吗?

您的作品也能展示在这里!点击提交,期待与您合作!

期待您的作品!

就像你看到的那样?

即时订阅将获取更多知识,并且直接发送到您的邮箱。支持随时退订。